Related Experiment Videos
[Phase II study of mitoxantrone for acute leukemia]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 1, 1984
Summary
Mitoxantrone shows effectiveness in treating acute leukemia patients, achieving complete remission in some previously untreated and treated cases. While myelosuppression is a risk, side effects are generally reversible.
Area of Science:
- Oncology
- Pharmacology
Context:
- Acute leukemia presents a significant therapeutic challenge.
- Previous treatments for acute leukemia often involve anthracycline derivatives.
Purpose:
- To evaluate the efficacy and safety of mitoxantrone as induction therapy for acute leukemia.
- To assess response rates in previously untreated versus previously treated patients.
Summary:
- Seventeen acute leukemia patients received mitoxantrone induction therapy.
- Complete remission (CR) rates were 33% in untreated and 25% in treated patients.
- Myelosuppression was the primary adverse event, though reversible.
Impact:
- Mitoxantrone demonstrates potential efficacy in select acute leukemia cases.
- Understanding mitoxantrone's safety profile, particularly myelosuppression, is crucial for clinical application.